RDInvesting Provides Investors with Free In-Depth Equity Reports on DHR, NX, SBGI and TLOG

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.

Danaher Corporation (NYSE:DHR - News) shares increased 2.19 percent to close at $75.65 a share Wednesday. The stock traded between $74.38 and $75.71 on volume of 3.07 million shares traded. Analysts at ISI Group have recently upgraded the company’s rating to "strong buy" from "buy". Shares of Danaher have fallen approximately 2.0 percent year-to-date.

Find out more about Danaher including full access to the free equity report at:
www.RDInvesting.com/DHR

Quanex Building Products Corporation (NYSE:NX - News) shares increased 4.24 percent to close at $20.92 a share Wednesday. The stock traded between $20.40 and $21.14 on volume of 360,327 shares traded. Analysts at BB&T Capital Markets have recently upgraded the company’s rating to "buy" from "hold". Shares of Quanex Building Products have gained approximately 5.0 percent year-to-date.

Find out more about Quanex Building Products including full access to the free equity report at:
www.RDInvesting.com/NX

Sinclair Broadcast Group Inc. (NASDAQ:SBGI - News) shares spiked 6.36 percent to close at $29.11 a share Wednesday. The stock traded between $28.02 and $29.28 on volume of 4.45 million shares traded. Analysts at Wells Fargo have recently upgraded the company’s rating to "outperform" from "market perform". Shares of Sinclair Broadcast Group have fallen approximately 18.0 percent year-to-date.

Find out more about Sinclair Broadcast Group including full access to the free equity report at:
www.RDInvesting.com/SBGI

Tetralogic Pharmaceuticals Corp. (NASDAQ:TLOG - News) shares gained 13.09 percent to close at $7.69 a share Wednesday. The stock traded between $6.94 and $7.85 on volume of 169,212 shares traded. Analysts at WBB Securities have recently upgraded the company’s rating to "buy" from "speculative buy". Shares of Tetralogic Pharmaceuticals have fallen approximately 20.0 percent year-to-date.

Find out more about Tetralogic Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/TLOG

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com